2026-01-06 - Analysis Report
Okay, here's a comprehensive analysis of Eli Lilly (LLY) based on the data provided.

**1. Return Rate Comparison:**

*   **Company Overview:** Eli Lilly and Co. is a global pharmaceutical company discovering and developing innovative medicines.
*   **LLY Cumulative Return:** 281.68%
*   **VOO Cumulative Return:** 91.00%
*   **Divergence:**
    *   Absolute Divergence: 190.68% (LLY significantly outperformed the S&P 500)
    *   Relative Divergence: 83.9 (This indicates that the current divergence is in the upper 84th percentile of its historical range relative to the S&P 500)

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta | Cap(B) |
|------------|--------|-------|---------|------|--------|
| 2016-2018  | 37.0%  | 14.3% | 33.0%   | 0.7  | 100.0  |
| 2017-2019  | 36.0%  | 14.7% | 19.0%   | 0.7  | 113.6  |
| 2018-2020  | 30.0%  | 20.9% | 10.0%   | 0.7  | 145.9  |
| 2019-2021  | 49.0%  | 20.9% | 5.0%    | 0.7  | 238.7  |
| 2020-2022  | 59.0%  | 20.9% | 60.0%   | 0.7  | 316.2  |
| 2021-2023  | 116.0% | 18.0% | 115.0%  | 0.5  | 503.8  |
| 2022-2024  | 123.0% | 27.0% | 104.0%  | 0.6  | 667.2  |
| 2023-2025  | 183.0% | 29.9% | 121.0%  | 0.7  | 928.8  |

*   **Analysis:**
    *   **CAGR:**  The Compound Annual Growth Rate has increased significantly in recent years, peaking in the 2023-2025 period. This indicates a period of very strong growth.
    *   **MDD:** Maximum Drawdown has also increased slightly recently, suggesting increased volatility and risk.
    *   **Alpha:**  Alpha is consistently positive and very high, indicating that LLY has outperformed its benchmark even after accounting for market risk (Beta). The jump in Alpha in recent periods (2020-2025) is particularly noteworthy.
    *   **Beta:** The Beta is consistently below 1, suggesting LLY is less volatile than the overall market (S&P 500).
    *   **Cap(B):** Market Capitalization has seen substantial growth, reflecting investor confidence and company performance.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 1080.36 (previous close); 1041.51 (last market price)
*   **Change:** -3.6%
*   **Moving Averages:**
    *   5-day SMA: 1078.254
    *   20-day SMA: 1046.905
    *   60-day SMA: 968.3677

*   **Analysis:** The current market price is significantly below the previous close. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, suggesting that the price has been on an upward trend, but the recent drop may indicate a short-term correction.

**3. Indicators and Signals:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommendation)
*   **RSI:** 76.97 (Overbought territory – potentially indicating a price correction)
*   **PPO:** -0.1559 (Slightly negative, suggesting a potential weakening of the upward trend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) This signal advises a fully invested position.
*   **Recent Divergence Change:** 0.6 (+) (Short-term increase)
*   **Expected Return:** 47.3% (Significant expected excess return over the S&P 500 for long-term investment)

*   **Analysis:**
    *   The RSI being in overbought territory, coupled with the negative PPO, suggests caution. The recent price drop (-3.6%) is likely a reflection of this.
    *   However, the MRI indicating a medium investment recommendation and the high expected return suggest that, despite short-term volatility, the long-term outlook remains positive.
    *   The hybrid signal's strong buy recommendation indicates overall positive sentiment from the automated system.

**4. Recent News & Significant Events (Yahoo Finance):**

*   **Negative:**
    *   "Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S." - This highlights increased competition in the lucrative obesity drug market.
    *   "Is It Time to Dump Your Shares of Eli Lilly?" - Raises concerns, though the article's reasoning would need to be analyzed.
    *   "I Expect Novo Nordisk To Outperform Eli Lilly In 2026" - Reinforces the competitive threat from Novo Nordisk.
*   **Positive/Neutral:**
    *   "LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?" - Acknowledges recent gains, but questions sustainability.
    *   "Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China" - Indicates market activity in China.
    *   "Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?" - Highlights analyst optimism, but also suggests further investigation.

*   **Analysis:**  The news is mixed, with a clear concern about increasing competition from Novo Nordisk, particularly in the obesity drug market. This competition is likely contributing to the recent stock price decline. However, analyst opinions generally remain positive.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (1.70 on a 1-5 scale)
*   **Target Price:** Average: $1098.04, High: $1500.00, Low: $770.00

*   **Analysis:**  Analysts, on average, maintain a "Buy" rating on LLY with a target price above the current price. However, the wide range between the high and low target prices suggests uncertainty and varying opinions on the stock's potential.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-10-30 | 6.22  | 17.60 B$    |
| 2025-08-07 | 6.3   | 15.56 B$    |
| 2025-05-01 | 3.07  | 12.73 B$    |
| 2024-10-30 | 1.08  | 11.44 B$    |
| 2025-10-30 | 1.08  | 11.44 B$    |

*   **Analysis:**
    *   Both EPS (Earnings Per Share) and Revenue have shown strong growth in recent quarters. The EPS figures for 2025-10-30 and 2025-08-07 are particularly impressive compared to previous periods. The latest earning information is same with 2024-10-30.
    *   This growth trend suggests strong business performance and positive market demand for LLY's products.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B    | 82.91%        |
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-09-30   | $23.79B    | 23.46%   |
| 2025-06-30   | $18.27B    | 30.98%   |
| 2025-03-31   | $15.76B    | 17.50%   |
| 2024-12-31   | $14.19B    | 31.07%   |
| 2024-09-30   | $14.24B    | 6.81%    |

*   **Analysis:**
    *   **Revenue:**  Consistent growth in revenue over the past five quarters is evident.
    *   **Profit Margin:**  Extremely high and stable profit margins, indicating strong pricing power and efficient cost management.
    *   **Equity:**  Increasing equity indicates the company is retaining earnings and growing its asset base.
    *   **ROE:**  High ROE (Return on Equity) figures demonstrate efficient utilization of shareholder investments to generate profits.

**7. Comprehensive Analysis (Summary):**

*   **Overall:** Eli Lilly has significantly outperformed the S&P 500, driven by strong growth, high profitability, and positive market sentiment.
*   **Strengths:**
    *   Exceptional CAGR and Alpha.
    *   High and stable profit margins.
    *   Strong revenue and earnings growth.
    *   Positive analyst ratings.
*   **Weaknesses/Risks:**
    *   Increased competition in the obesity drug market, particularly from Novo Nordisk.
    *   Overbought RSI and recent price decline suggest potential short-term correction.
    *   Relatively high Maximum Drawdown (MDD).
*   **Outlook:**
    *   The long-term outlook for LLY appears positive, driven by its innovative drug pipeline and strong financial performance.
    *   However, investors should be aware of the increasing competition and potential for short-term volatility.
    *   Monitoring news related to the competitive landscape and LLY's drug development pipeline is crucial.

In conclusion, while recent news and technical indicators suggest a potential short-term correction, Eli Lilly's strong fundamentals, impressive growth, and positive analyst sentiment point towards a potentially positive long-term investment opportunity. Investors should carefully weigh the risks and rewards before making any decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.